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Case Report
Waldenstrom's Macroglobulinemia terminating in acute Myeloid Leukemia
Safoorah Khalid, Salman Naseem Adil, Mohammad Khurshid
Department of Pathology and Microbiology, Aga Khan University Hospital, Karachi.
Abstract
Waldenstrom's macroglobulinemia (WM) is a rare
condition, accounting for approximately 2% of haematolog-
ic malignancies. The most common causes of death in these
patients are progression of the malignant lymphoprolifera-
tive process, infection and cardiac failure. Acute leukemia is
a rare event in the clinical course of WM.  A number of case
reports have documented the development of terminal acute
leukemia in patients with WM following prolonged
chemotherapy.
We describe a case of an elderly man who was a
diagnosed case of WM and treated with chlorambucil and
cyclophosphamide. Four years later, he developed acute
leukemia. 
Introduction
Waldenstrom's macroglobulinemia (WM) is a rare
condition, accounting for approximately 2% of haematolog-
ic malignancies.1 It is almost entirely a disease of elderly,
with a peak incidence in the sixth and seventh decades.
Clinically overt WM may follow a long period of benign
monoclonal gammopathy. The common presenting features
are weakness and fatigue, haemorrhagic manifestations,
weight loss, neurologic symptoms, visual disturbances and
Raynaud’s phenomenon. As the        disease progresses,
hepatomegaly, splenomegaly and lymphadenopathy
become prominent features. In WM, the signs and symp-
toms of hyperviscosity syndrome are related to the circula-
tory disturbances caused by the increased resistance to
blood flow. Conventional treatment regimen includes alky-
lating agents such as chlorambucil or cyclophosphamide.
The most common causes of death in these patients are pro-
gression of the malignant lymphoproliferative process,
infection and cardiac failure.2 The development of acute
leukemia has also been rarely described as a preterminal
event and it has been reported to occur following prolonged
chemotherapy with alkylating agents in majority of the
cases.
Case Report
A 75 years old gentleman presented in September
2001 with history of angina. General physical examination
revealed pallor. There was no evidence of lymphadenopathy
and hepatosplenomegaly. Laboratory data were as follows:
haemoglobin   9.1gm/dl,   WBC 9.6x109/L,   platelets 
230x109/L and ESR 108 mm/hr.
A bone marrow was done which revealed 40% lym-
phoplasmacytoid and plasma cells. Immunofixation
electrophoresis showed IgM kappa light chains. Serum IgM
levels were found to be 42.2gm/dl. Thus he was diagnosed
to have WM. Chlorambucil was prescribed at the dose of
10mg/day for twelve months followed by cyclophos-
phamide 150mg/day for fifteen days every month for four
months. He also required off and on packed cell transfu-
sions during the course of his treatment.
In March 2005, he presented with pallor and altered
behaviour and speech. Examination was unremarkable. His
CBC revealed haemoglobin 9.7gm/dl, WBC 29.8x109/L,
platelets 30x109/L, 40% blast cells were present on the
peripheral film and bone marrow findings were consistent
with acute myeloid leukemia. The patient refused further
treatment and died within one month.
Discussion
The development of terminal acute leukemia in
patients with WM appears to be a rare event. Literature
review reveals various case reports.3-6 A vast majority of
WM were complicated by acute myeloid leukemia.
However, one case of acute lymphoid leukemia has been
reported.6 A therapy-related myelodysplastic syndrome dur-
ing the course of WM has also been observed in rare
patients.7 In most of them, the condition developed after
treatment with alkylating agents. It may also occur rarely in
an untreated case of WM.8
In majority of cases including ours, there was a his-
tory of treatment with one of the alkylating agents. In con-
trast, acute leukemia rarely complicates chronic lymphocyt-
ic leukemia even with long term treatment with alkylating
agents. The rarity with which acute leukemia is encountered
in this disorder would suggest that in the well differentiated
lymphoproliferative disorders, alkylating agents are not
involved in leukemogenesis.9 Although in those patients
who received treatment for their WM, acute leukemia sec-
ondary to this therapy seems to be the most widely accept-
ed etiological theory; the possible etiology of non-treated
cases remains controversial.10 One theory postulates that
leukemia may have arisen from a different clone of cells
either secondary to the same etiologic agent that produced
the WM or secondary to another etiologic factor.5
Response to treatment is poor and survival is very
short.5 In light of various case reports including ours, leuke-
mogenic potential of alkylating agents in WM would 
appear to warrant further scrutiny. 
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